GeneDx Holdings (WGS) Accounts Payables (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Accounts Payables data on file, last reported at $46.6 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $46.6 million, up 11.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.6 million (up 11.23% YoY), and the FY2025 annual result was $57.6 million, up 86.05% from the prior year.
• Accounts Payables slipped to $46.6 million in Q1 2026 per WGS's latest filing, from $57.6 million in the prior quarter.
• Over five years, Accounts Payables peaked at $115.9 million in Q2 2022 and troughed at $31.0 million in Q4 2024.
• A 5-year average of $57.3 million and a median of $52.0 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 156.19% in 2022, then slumped 55.87% in 2023.
• A 5-year view of Accounts Payables shows it stood at $84.9 million in 2022, then slumped by 55.87% to $37.5 million in 2023, then fell by 17.28% to $31.0 million in 2024, then surged by 86.05% to $57.6 million in 2025, then retreated by 19.23% to $46.6 million in 2026.
• Business Quant data shows WGS's Accounts Payables at $46.6 million in Q1 2026, $57.6 million in Q4 2025, and $50.3 million in Q3 2025.